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chemotaxic activity in cattle
Satoru Takanashi1,2, Tomonori Nochi1,2*, Miku Abe1,2, Nanami Itaya1, Megumi Urakawa1,2, Katsuyoshi Sato1,
Tao Zhuang1,2, Saori Umemura1, Tomohito Hayashi3, Yoshio Kiku3, Haruki Kitazawa2,4, Michael T. Rose5,
Kouichi Watanabe1,2 and Hisashi Aso1,2Abstract
Cyclophilin A (CyPA) was originally discovered in bovine thymocytes as a cytosolic binding protein of the
immunosuppressive drug cyclosporine A. Recent studies have revealed that in mice and humans, CyPA is
secreted from cells in injured or infected tissues and plays a role in recruiting inflammatory cells in those
tissues. Here we found that in cattle abundant level of extracellular CyPA was observed in tissues with inflammation. To
aid in investigating the role of extracellular CyPA in cattle, we generated recombinant bovine CyPA (rbCyPA) and tested
its biological activity as an inflammatory mediator. When bovine peripheral blood cells were treated with rbCyPA
in vitro, we observed that rbCyPA reacts with the membranous surface of granulocytes, monocytes and lymphocytes.
Chemotaxis analysis showed that the granulocytes migrate toward rbCyPA and the migration is inhibited by
pre-treatment with an anti-bovine CyPA antibody. These results indicate that, as for mice and humans, extracellular CyPA
possesses chemotactic activity to recruit inflammatory cells (e.g., granulocytes) in cattle, and could thus be a potential
therapeutic target for the treatment of inflammation.Introduction
Inflammation occurs when tissues are injured by exposure
to pathogens (e.g., bacteria, viruses) or foreign substances
(e.g., toxins, chemicals) [1]. Chemokines, which are small
cytokines sharing a basic structure composed of three anti-
parallel β-strands and an overlying α-helix, play a key role
in regulating leucocyte trafficking into inflammatory tissues
[2]. So far, nearly 50 kinds of chemokine belonging to either
the CXC, CC, C or CX3C families have been identified; all
have important roles, not only in inflammation but also
homeostatic responses [3]. However, recent studies have
shown that, in addition to chemokines, other factors with-
out the structural characteristics peculiar to the chemo-
kines, are also involved in leucocyte trafficking as they also
possess potent chemotactic activity [4].
Cyclophilins, which consist of 16 members in humans,
are a family of peptidyl prolyl cis-trans isomerases [5,6].* Correspondence: nochi@m.tohoku.ac.jp
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creativecommons.org/publicdomain/zero/1.0/Cyclophilin A (CyPA), which is the most abundant member
of the family, has multiple biological roles in protein fold-
ing, trafficking, T cell activation and cell signaling [5]. CyPA
also acts as the intracellular receptor for the immunosup-
pressive drug cyclosporin A [7]. CyPA had been believed to
be present only in the intracellular space, but recent studies
have shown that it is secreted from cells in response to hyp-
oxia, infection and oxidative stress [8]. An example is that
the reactive oxygen species induces CyPA secretion from
vascular smooth muscle cells (VSMCs), resulting in the
formation of abdominal aortic aneurysms (AAA), in which
abnormal proliferation of VSMCs, unusual expression of
endothelial cell adhesion molecule, and aberrant infiltration
of inflammatory cells in the aortic wall are observed [9,10].
CD147 (also known as extracellular matrix metallo-
proteinase inducer; EMMPRIN) has been known to act as
the main signaling receptor for extracellular CyPA [11].
Leucocyte migration toward CyPA is essentially regulated
by CD147 [11–14]. In mice CD147 expression is found on
lymphocytes, monocytes and granulocytes present in per-
ipheral blood [12], such that these cells could recognize
CyPA and migrate into injured tissues where CyPA is se-
creted. Treatment with anti-CD147 monoclonal antibodys article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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Therefore, interference of CyPA-CD147 interaction would
be a novel potential therapeutic to reduce infiltration of
inflammatory cells into injured tissues.
Inflammation caused by infection with bacteria or vi-
ruses in cattle, such as during mastitis and pneumonia,
is a serious problem in the dairy cattle industry because
such diseases are directly linked to a significant financial
loss [15,16]. Numerous strategies have been developed
for the prevention and cure of these diseases [17,18], but
their incidence across the industrialized world is still
high, and therefore more research is still required in
order to reduce the mortality and morbidity caused.
Moreover, more precise mechanisms by which inflam-
matory cells migrate into the injured tissues from
peripheral blood in cattle must be addressed.
Here we show that abundant levels of extracellular
CyPA is found in the mammary gland during mastitis.
Using recombinant bovine CyPA (rbCyPA), we demon-
strate that extracellular bovine CyPA is involved in
recruiting inflammatory cells (e.g., granulocytes). These
results indicate that extracellular CyPA could possess
chemotaxic activity to induce inflammation in cattle.
Materials and methods
Animal studies
Mammary tissue (n = 6) and peripheral blood cells
(n = 3) were obtained from 9 Holstein dairy cows. All
animal studies were performed in accordance with pro-
tocols approved by Tohoku University Institutional Ani-
mal Care and Use Committee.
Immunohistochemistry
Mammary gland tissues collected from cattle with (n = 3)
and without (n = 3) mastitis were fixed in 4% (w/v) of para-
formaldehyde (PFA) or periodate lysine paraformaldehyde
(PLP) overnight at 4 °C, and embedded in paraffin. Tissue
sections (3 μm) were first subjected to antigen retrieval
using a REAL™ target retrieval solution (DAKO). After
blocking with 3% (v/v) of normal goat serum (Vector), the
sections were stained with 1 μg/mL of rabbit anti-mouse/
rat/human CyPA antibody (Abcam, Catalog No: ab41684,
hereafter called the commercial anti-CyPA antibody), which
is predicted to react to bovine CyPA according to the
manufacturer’s data sheet, or 1 μg/mL of control rabbit im-
munoglobulin (Dako). The sections were then stained with
Histofine® Simple Stain MAX PO (R) (Nichirei Biosciences)
and the signal was developed with 3,3′-diaminobenzidine
tetrahydrochloride (DAB). Finally, counterstaining with
hematoxylin was performed.
Recombinant bovine CyPA (rbCyPA)
The gene coding bovine CyPA was synthesized by PCR
with PrimeStar® HS DNA polymerase (Takara) and specificprimers (sense, 5′-TAGCTCAAGCTTTGATGGTCAACC
CCACCGTGTTCTTC-3′; antisense, 5′-CGCTCGCTCGA
GTTAGATTTGTCCACAGTCAGCAAT-3′; HindIII and
XhoI restriction enzyme sites are shown by underlining).
PCR fragment and the expression vector pPAL7 (Bio-Rad)
were digested with HindIII and XhoI, and were ligated with
DNA ligation kit ver. 2.1 (Takara). After DNA sequencing,
the plasmid was used to transform BL21 (DE3) (Bio-Rad),
and the cells were treated with 0.1 mM of isopropyl-β-D-
thiogalactopyranoside (IPTG) for 4 h at 37 °C to induce
Profinity eXact-tagged bovine CyPA expression. The cells
were then suspended in PBS and sonicated. After centrifu-
gation, the supernatant was loaded onto a column packed
with Profinity eXact™ Purification Resin (Bio-Rad) that has
enzymatic activity to cleave between the Profinity eXact tag
and rbCyPA. Tag-free rbCyPA obtained by affinity chroma-
tography was finally loaded onto a Sephacryl S-100 column
(GE Healthcare) to prepare highly purified rbCyPA. SDS-
PAGE and western-blotting with the commercial anti-
CyPA antibody (Abcam) or control rabbit immunoglobulin
(Dako) were performed to confirm the expression and
purification of rbCyPA. A portion of the rbCyPA was
conjugated with fluorescein isothiocyanate (FITC), Isomer I
on Celite (Sigma), which has the thiocyanate group that
crosslinks with amino group on rbCyPA. To determine
whether the reactivity of the commercial anti-CyPA anti-
body (Abcam) was neutralized by pre-incubation with
rbCyPA, 1 mg/mL of rbCyPA was treated with the 10 μg/mL
of the commercial anti-CyPA antibody for 1 h at room
temperature (RT), and the mammary gland tissue sections
were treated with the antigen-antibody complex after
dilution with PBS (1:10, final antibody concentration
was 1 μg/mL, consistent with the regular staining
protocol for immunohistochemistry).
Binding analysis
Bovine peripheral blood was obtained from jugular vein
and heparinized. Erythrocytes were lysed using 0.83%
(w/v) of ammonium chloride. The cells were suspended
in PBS (1.0 × 106 cells /100 μL) and incubated with
10 μg/mL of either rbCyPA or bovine serum albumin
(BSA) (Sigma), both of which were pre-conjugated with
FITC (Sigma), for 10, 60, 120, 240 and 360 min at 37 °C.
After incubation, flow cytometry data were collected
using a BD Accuri™ C6 flow cytometer (BD Bioscience),
and analyzed 1 × 104 cells using BD Accuri™ C6 software
(BD Bioscience) and FCS Express 5 (De Novo Software).
Mouse anti-bovine granulocyte antibody (MM20A,
mouse IgG1, 20 μg/mL), mouse anti-bovine CD14
antibody (DG-CAN36A, mouse IgG1, 20 μg/mL),
mouse anti-bovine CD3 antibody (MM1A, mouse IgG1,
20 μg/mL) and isotype control mouse IgG1 (COLIS69A,
20 μg/mL), all of which were purchased from Washington
State University Monoclonal Antibody Center, were used to
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FITC-conjugated rbCyPA and FITC-conjugated BSA.
Via-Probe™ (BD Bioscience) was used to exclude dead cells.
Rabbit anti-bovine CyPA polyclonal antibody
A rabbit was immunized with rbCyPA 6 times every
week at Eurofins Genomics K.K. to obtain large amount
of anti-bovine CyPA polyclonal antibody, enough for an
inhibition study. This was because the commercial anti-
CyPA antibody (Abcam) was not available in sufficient
amounts for testing our hypothesis that a CyPA-targeted
therapeutic could be an effective strategy for the treat-
ment of inflammation. The first three immunizations
were all performed subcutaneously with 200 μg of
rbCyPA plus Freund’s complete adjuvant, and the last
three immunizations were performed intravenously with
25, 50 and 50 μg of rbCyPA, respectively. Serum samples
were collected before the first immunization and after
the final booster. After IgG purification with Protein G
(GE Healthcare), these serum samples were for use as
the control antibody and anti-bCyPA antibody, respect-
ively. IgG titers of anti-bCyPA antibody and control anti-
body against rbCyPA were measured by ELISA. Briefly,
96-well ELISA plates (Nunc) were coated with rbCyPA
(2 μg/mL, 100 μL) overnight at 4 °C. After blocking with
1% BSA in TBST [50 mM Tris–HCl (pH 8.0), 0.05%
Tween-20] for 1 h at RT, diluted IgG antibodies were
incubated for 2 h at RT. After washing, the plates were
treated with HRP-conjugated donkey anti-rabbit IgG
(Jackson Immunoresearch) diluted 1:20 000 for 1 h at
RT and the signals were finally developed with a TMB
microwell peroxidase substrate system (KPL).
Chemotaxis analysis
Granulocytes were used for a chemotaxis analysis with
rbCyPA. In brief, peripheral blood mononuclear cells in
cattle (n = 2) were removed by centrifugation with
Lympholyte-H (Cedarlane) and erythrocytes were then
lysed with 0.83% (w/v) of ammonium chloride to obtain
the granulocytes. To confirm their purity, flow cytome-
try analysis with mouse anti-bovine granulocyte antibody
(MM20A, Washington State University Monoclonal
Antibody Center) was performed. For the chemotaxis
analysis, a cell migration assay using Transwell® inserts
with 5.0 μm pore polycarbonate membrane (Corning)
were performed, as described previously [19]. Briefly,
granulocytes suspended in STEMPRO® (Gibco, 1.0 × 106
cells/cm2/100 μL) were cultured in the upper chambers
of the inserts and several different concentrations (0, 30,
50, 100, 300 or 500 ng/mL, 600 μL) of rbCyPA were
added into the lower chambers (24 well plates). In some
experiments, rbCyPA (100 ng/mL) was pre-incubated
with 100 μg/mL of either anti-bCyPA antibody or the
control antibody for 60 min at RT. After incubation for90 min at 37 °C in a 5% CO2 incubator, the membranes
of the transwell® inserts were stained with Giemsa
reagent (Nacalai tesque). In an each experimental condi-
tion, 15 or 16 images (76 800 μm2 / image) were ob-
tained from 3 or 4 membranes using a microscope
AX70 (Olympus) and the numbers of granulocytes mi-
grating to the lower chamber of the insert were counted
manually.
Statistical analysis
All statistical analyses (alpha level: 0.01) were performed
in Prism version 6 (GraphPad). Two-way repeated meas-
ure ANOVA and Tukey’s multiple comparison test were
performed for Figure 3, One-way factorial ANOVA and
Tukey’s multiple comparison tests were performed for
Figures 4 and 5.
Results
Secretion of CyPA in mammary gland of cattle with
mastitis
As CyPA in mice and humans has been known to be
secreted from cells during inflammation, such as abdom-
inal aortic aneurysms (AAA), our initial study was de-
signed to investigate whether extracellular CyPA was
also found in cattle during inflammation. When mam-
mary gland tissues sampled from cattle with or without
mastitis were analyzed by immunohistochemistry with
the commercial anti-CyPA antibody, we found that,
regardless of the presence of mastitis, CyPA was present
in the cytoplasm of mammary epithelial cells (Figure 1).
Importantly, however, abundant levels of extracellular
CyPA were only detected in the alveoli and ducts in
mammary tissues from mastitic cattle (Figure 1). We
also found that inflammatory cells expressing CyPA were
highly recruited in stromal tissue of mammary gland
with mastitis. No signals were detected in sections stained
with the control rabbit immunoglobulin (Figure 1). These
results indicate that, as in mice and humans, CyPA is
secreted from cells in cattle during inflammation, such
as mastitis.
Expression and purification of recombinant bovine CyPA
(rbCyPA)
In order to address the role of extracellular CyPA in cat-
tle, rbCyPA was produced and its biological activity was
determined. An expression plasmid (pbCyPA-PAL7,
6363 bp), in which the bovine CyPA gene was inserted
in the downstream of Profinity eXact tag sequence, was
constructed (Figure 2A). E. coli (BL21) was transformed
with pbCyPA-PAL7 and treated with IPTG to induce the
expression of Profinity eXact-tagged bovine CyPA. SDS-
PAGE analysis showed that one major band of approxi-
mately 26 kDa was detected only when the BL21 cells
were cultured with IPTG (Figure 2B, lanes 2 and 3).
A)
B)
C)
D)
E)
F)
G)
H)
Normal Mastitis
Figure 1 CyPA is secreted in cattle during inflammation.
Immunohistochemical analysis shows that extracellular CyPA
is abundantly found in alveoli and ducts of bovine mammary
gland with mastitis (shown by arrowheads). A-C and E-G (both
of which were stained with anti-CyPA antibody) are images
showing individual healthy cattle and individual cattle with
mastitis, respectively. D (healthy) and H (mastitis) are images
stained with control antibody. Scale bar = 100 μm.
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cells were sonicated and the supernatant was loaded on
the SDS-PAGE gel (Figure 2B, lane 4). These results
indicated that the vast majority of the Profinity eXact-
tagged bovine CyPA expressed in BL21 cells was a sol-
uble protein. After affinity and gel chromatography with
the supernatant, we observed a single band of approxi-
mately 16 kDa (Figure 2B, lane 5). Subsequent western-
blot analyses showed that the band was recognized when
the commercial anti-CyPA antibody, not control rabbit
immunoglobulin, was used (Figure 2C). We also con-
firmed by a neutralizing study that the reactivity of the
commercial anti-CyPA antibody used for immunohisto-
chemistry (shown in Figure 1) was completely blocked
by pretreatment with the generated rbCyPA (Figure 2D).
Given that Profinity eXact™ Purification Resin used foraffinity chromatography has the enzymatic activity to
cleave between Profinity eXact tag and rbCyPA [20],
tag-free rbCyPA obtained was used for the next in vitro
analyses in order to address the role of extracellular
CyPA in cattle.
Binding analysis with rbCyPA
In order to investigate the reaction of rbCyPA with im-
mune cells in cattle, we performed an in vitro binding
analysis with rbCyPA. Immune cells collected from bo-
vine peripheral blood were first analyzed by flow cytom-
etry using three antibodies: anti-bovine granulocyte
antibody (MM20A), which reacts highly to granulocytes
and slightly with monocytes; anti-bovine CD14 antibody
(DG-CAN36A), which specifically binds to monocytes;
and anti-bovine CD3 antibody (MM1A), which reacts
with T cells. This was to develop a gating strategy for the
in vitro binding analysis. We observed that granulocyte
+CD14−CD3− cells, granulocytelowCD14+CD3− cells and
granulocyte−CD14+CD3+ or – cells, which correspond to
granulocytes, monocytes and lymphocytes, respectively,
were observed in three major populations; these were
named gate 1, gate 2 and gate 3 on a FSC and SSC pro-
file (Figure 3A). These results indicated that the gating
strategy based on the FSC and SSC profile could be used
for distinguishing the three major cell types (i.e., granu-
locytes, monocytes and lymphocytes) without any add-
itional time restriction for staining using anti-bovine
granulocyte, anti-bovine CD14 and anti-bovine CD3
antibodies after in vitro study. To address whether extra-
cellular CyPA reacts to immune cells in cattle, we next
prepared FITC-conjugated rbCyPA (FITC-CyPA) and
used it for an in vitro binding analysis. We found that,
depending on the reaction time, the reactivity of rbCyPA
to all three cell types was increased gradually (Figure 3B).
Importantly, the reactivity to immune cells was higher
than that of FITC-conjugated BSA (FITC-BSA) used as a
control (Figure 3B). These results indicated that the
receptor for extracellular CyPA could be present in all of
the immune cells analyzed.
Chemotaxis analysis with rbCyPA
In order to analyze the role of extracellular CyPA in cattle,
we performed a chemotaxis analysis with rbCyPA. Among
the three major white blood cell populations (granulo-
cytes, monocytes and lymphocytes) present in peripheral
blood (Figure 3A), we focused on investigating granulo-
cytes because neutrophils, which are the major popula-
tion among granulocytes, initially migrate into injured
tissues to induce inflammatory responses [21]. When
we enriched granulocytes from peripheral blood cells by
density-gradient centrifugation with Lympholyte-H, the ratio
of granulocytes recognized by anti-bovine granulocyte anti-
body exceeded 90% (Figure 4A). We next cultured the
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Figure 2 Recombinant bovine CyPA (rbCyPA) is generated in an E.coli expression system. A pbCyPA-PAL7 (6363 bp) was constructed to
express rbCyPA in E.coli (BL21). B SDS-PAGE analysis showed that Profinity eXact-tagged rbCyPA was expressed when BL21 cells were treated with
IPTG and obtained as a soluble protein. Tag-free rbCyPA was collected after affinity and gel chromatography. Lane 1: molecular weight marker,
2: Cell lysate of BL21 cells cultured without IPTG, 3: Cell lysate of BL21 cultured with IPTG, 4: Soluble proteins obtained by sonication of cell lysate
of BL21 cultured with IPTG, 5: rbCyPA collected after affinity and gel chromatography. C Western-blot analysis was conducted using the commercial
anti-CyPA antibody (1) or the control rabbit immunoglobulin (2) to confirm that the band shown on lane 5 of Figure 2B was bovine CyPA. D Neutralization
with rbCyPA completely inhibited the immunoreactivity of anti-CyPA antibody used for immunohistochemistry. Scale bars = 100 μm.
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A)
B)
Figure 3 rbCyPA binds to granulocytes, monocytes and lymphocytes present in bovine peripheral blood. A A gating strategy for flow
cytometry analysis was established by staining with anti-bovine granulocytes, CD14 or CD3. Three major populations (gate 1, 2 and 3) were found
on the FSC and SSC profiles of bovine peripheral blood cells (1 left panel). Cells present in gate 1, 2 and 3 were granulocytes, monocytes and lymphocytes,
respectively, because these were granulocyte+CD14−CD3− cells, granulocytelowCD14+CD3− cells and granulocyte−CD14+CD3+ or – cells (9 right
panels), respectively. B rbCyPA reacted to granulocytes, monocytes and lymphocytes in a time-dependent manner. Longitudinal change is
shown in the line graph on the right. Three separate experiments were performed and the data represent means ± SEM. Values with different
letters are statistically different (p < 0.01).
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A)
B)
C)
Figure 4 rbCyPA possesses chemotactic activity. A Granulocytes were purified by centrifugation with Lympholyte-H and the purification was confirmed
by staining with anti-granulocyte antibody. B Chemotactic analysis with several different concentration of rbCyPA was performed. Granulocytes migrating
toward rbCyPA are shown. 1: 0 ng/mL, 2: 30 ng/mL, 3: 50 ng/mL, 4: 100 ng/mL, 5: 300 ng/mL, 6: 500 ng/mL of rbCyPA. C Chemotactic activity was
evaluated by counting of granulocytes that migrated toward rbCyPA. Three separate experiments were performed and one representative result is shown.
Values with different letters are statistically different (p< 0.01).
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A)
B)
C)
Figure 5 rbCyPA-mediated chemotactic activity was inhibited by
the use of anti-bovine CyPA antibody. A Rabbit anti-bovine CyPA
polyclonal antibodies were generated by immunization with rbCyPA.
Serum was collected both before the first immunization (arrow) and after
the final booster (red arrow) to obtain the control and anti-bovine CyPA
antibodies, respectively. Bovine CyPA-specific antibody titers were
measured by ELISA. SC: subcutaneous injection, IV: intravenous injection.
B and C Chemotactic analysis was performed after pre-treatment with
100 ng/mL of rbCyPA with 100 μg/mL of either the anti-bovine CyPA
antibody or control antibody. rbCyPA-mediated chemotactic activity was
inhibited by pre-treatment with anti-bovine CyPA antibody (not control
antibody). B 1: no rbCyPA+ no antibody, 2: 100 ng/mL of rbCyPA+ no
antibody, 3: 100 ng/mL of rbCyPA+ 100 μg/mL of anti-bovine CyPA
antibody, 4: 100 ng/mL of rbCyPA+ 100 μg/mL of control antibody. C
Three separate experiments were performed and one representative result
is shown. Values with different letters are statistically different (p< 0.01).
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and stimulated the cells with several different concentra-
tions of rbCyPA added to the lower chambers. We found
that up to a concentration of 50 ng/mL of rbCyPA, the
granulocytes migrated toward rbCyPA in a dose-dependent
manner (Figures 4B and C). Interestingly, when concentra-
tions of greater than 50 ng/mL were tested, there was no
further increase in migration up to a concentration of
300 ng/mL; above a concentration of 500 ng/mL, the pro-
portion was decreased (Figures 4B and C). These results
indicate that 50–300 ng/mL of rbCyPA is the optimal
concentration to induce maximal rbCyPA-mediated
chemotactic activity in granulocytes.
Inhibition of rbCyPA-mediated chemotaxis by anti-bCyPA
antibody
We next designed a neutralizing study with an anti-bovine
CyPA antibody in order to consider the future possibility of
CyPA-targeted anti-inflammatory therapeutics. A rabbit
was immunized with rbCyPA 6 times and the antiserum
was collected 1 week after the final immunization (red
arrow in Figure 5A). As a control, serum was also collected
1 week before the first immunization (blue arrow in
Figure 5A). A high titer of bCyPA-specific IgG antibody
was observed when IgG purified from antiserum was ana-
lyzed by ELISA with rbCyPA-coated plates (Figure 5A). In
contrast, no detectable level of anti-bCyPA antibody was
found when IgG purified from control serum was examined
(Figure 5A). Thus, in our next study, we used IgG purified
from both antiserum and control serum as anti-bCyPA
antibody and control antibody, respectively. Given that
50–300 ng/mL of rbCyPA is the optimal concentration to
induce a maximal effect of rbCyPA-mediated chemotactic
activity in granulocytes (Figures 4B and C), we decided to
neutralize 100 ng/mL of rbCyPA with 100 μg/mL of either
anti-bCyPA antibody or control antibody. Consistent
with our previous study, as shown in Figures 4B and C,
100 ng/mL of rbCyPA showed an efficient chemotactic
activity to granulocytes. However, pretreatment with the
anti-bCyPA antibody inhibited the rbCyPA-mediated
chemotactic activity completely (Figures 5B and C). In
contrast, granulocyte migration toward rbCyPA was ob-
served as normal when rbCyPA pre-treated with control
antibody was used (Figures 5B and C). Taken together, the
neutralization of extracellular CyPA function could be a
potent immunotherapy for the prevention and cure of
inflammation across a range of diseases in cattle.
Discussion
CyPA is an evolutionarily conserved protein that is
present in the cytoplasm of all prokaryotes and eukary-
otes [6]. The amino acid sequence homology among
human, mouse and bovine CyPA is high (98.8%: bovine
vs human; 96.3%: human vs mouse; 95.1%: bovine vs
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mouse and bovine CyPA are almost identical (human:
18.0 kDa, mouse: 18.0 kDa and bovine: 17.9 kDa). Re-
cent studies have shown that CyPA is secreted from cells
in response to inflammatory stimuli and oxidative stress,
and that the role of extracellular CyPA differs from that
of intracellular CyPA in mice and humans [5]. We also
found that abundant level of extracellular CyPA is
present in tissues with inflammation in cattle (Figure 1),
but investigations to gain an insight into the role of
extracellular bovine CyPA have not yet been conducted.
Therefore, in this study, we first generated recombinant
bovine CyPA (rbCyPA) using an E. coli expression vector
pPAL7 (Figure 2A). The use of pPAL7 allows us to gen-
erate tag-free protein without any extra non-related
amino acid residues, as Profinity eXact™ Purification
Resin used for the affinity chromatography has enzym-
atic activity to cleave just before the first methionine
[20], which is the start codon of rbCyPA. SDS-PAGE
and western-blot analyses showed that highly purified
rbCyPA without any contaminated proteins was obtained
by affinity and gel chromatography (Figures 2B and C). As
a note, approximately 20 mg of purified rbCyPA was col-
lected from 20 liters of BL21 cell culture. Given this suffi-
cient quality and quantity of purified rbCyPA, we decided
to use it for our subsequent in vitro studies.
CD147, is a type I transmembrane protein and has been
known to act as a receptor for extracellular CyPA in mice
and humans [11–14]. CD147 is ubiquitously expressed on
many types of murine immune cells (e.g., lymphocytes,
monocytes and granulocytes), but no studies have been
conducted yet to demonstrate the expression of CD147 on
bovine immune cells due to the lack of a commercially
available anti-bovine CD147 antibody. Nevertheless, our
alternative approach, using rbCyPA conjugated with FITC
(FITC-CyPA), indicated that lymphocytes, monocytes and
granulocytes present in bovine peripheral blood have a re-
ceptor for extracellular CyPA because FITC-CyPA reacted
to all immune cells analyzed, in a time-dependent manner
when incubated in vitro (Figure 3B). We have not yet
obtained direct evidence to show that the receptor for
extracellular CyPA is CD147 in cattle, but this experiment
suggests that the binding molecule of extracellular CyPA
is expressed by bovine lymphocytes, monocytes and
granulocytes.
Neutrophils initially migrate into injured (or damaged)
tissues to initiate inflammatory responses [21]. In a
mouse model of acute lung inflammation, the level of
secretion of CyPA is increased dramatically when lipo-
polysaccharide is administered intra-nasally [12]. The
increased level of CyPA leads to CD147-mediated neu-
trophil recruitment into the lung tissues, such that
treatment with anti-CD147 antibody in this mouse
model inhibits the CyPA-CD147 interaction, resulting inreduced tissue neutrophilia with a concurrent decrease
in tissue pathology [12]. Therefore, the first priority of
our study was to investigate the role of extracellular CyPA
for neutrophils in cattle. Among the cell types: neutrophils,
eosinophils and basophils (all categorized as granulocytes),
neutrophils are the most abundant cell population [22].
Therefore, we used whole enriched granulocytes, the pur-
ity of which was more than 90% (Figure 4A). We found a
dose-dependent and bell-shaped curved reaction of
rbCyPA to bovine granulocytes (Figures 4B and C). More-
over, the optimal concentration that induced the max-
imum chemotactic activity was 50–300 ng/mL (Figures 4B
and C), which is consistent with a previous study showing
the chemotactic activity of extracellular CyPA in mice [12].
These results indicate that the role of extracellular CyPA is
highly conserved across species.
Antibody administration in patients to prevent the
function of pathogenic factors (e.g., proinflammatory
cytokines) or to attack the abnormal cells (e.g., cancer
cells) is widely known as an effective immunotherapy [23].
For example, anti-human tumor necrosis factor (TNF)
alpha-specific monoclonal antibody or anti-human CD20-
specific monoclonal antibody has been extensively used as
an innovative medicine for patients with rheumatoid arth-
ritis or leukemia [24,25]. Inhibition of extracellular CyPA
function using CyPA-specific neutralizing antibodies has
been also considered to be a potent immunotherapy,
because extracellular CyPA recruits inflammatory cells to
accelerate the abnormal immune responses [8]. Moreover,
in our study, we demonstrated that the function of extra-
cellular CyPA is also common to the bovine. Therefore, to
confirm our hypothesis that extracellular CyPA could be a
therapeutic target to prevent the recruitment of inflamma-
tory cells in cattle, we generated rabbit anti-bovine CyPA
polyclonal antibody. When 100 ng/mL of rbCyPA, which
is predicted to induce a maximum chemotactic activity,
was pre-treated with 100 μg/mL of rabbit anti-bovine
CyPA polyclonal antibody, the chemotactic activity was
completely removed (Figures 5B and C). We have not yet
estimated the financial aspects of a CyPA-targeted therapy
using an antibody in cattle. However, given the result
obtained in this proof-of-principal study showing the inhibi-
tory effect for the inflammatory cell influx through extracel-
lular CyPA, not only antibody therapies but also other
chemotherapeutics that inhibit the role of extracellular
CyPA could be considered as a practical approach to pre-
vent extracellular CyPA-mediated inflammation in cattle.
We demonstrated here that extracellular CyPA pos-
sesses chemotactic activity to recruit inflammatory cells in
cattle, and treatment with anti-bovine CyPA antibody is
capable of inhibiting the extracellular CyPA-mediated in-
flammatory cell trafficking. Taken together, extracellular
CyPA could be a potential therapeutic target for the treat-
ment and cure of inflammation in cattle.
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